LYF FOOD TECHNOLOGIES INC. (“LYF” or the “Company”) is pleased to announce that Health Canada has completed its preliminary high-level review of the Company’s Standard Processor License application. The Company will submit its evidence package to demonstrate that the Company’s site meets all the requirements of the Cannabis Act and applicable regulations to Health Canada in the coming weeks.

“Our team has worked tirelessly over the last 2 years to bring this dream to reality, and can now confidently say we are in the last steps of the Health Canada licensing process. Our facility will be completed in approximately 2 weeks and then our regulatory partners at CCI Deloitte will assist in the submission of our site evidence package to Health Canada. We are excited at the prospect of being one of the first licensed edibles companies in Canada, and a first mover in Cannabis 2.0 consumer products,” said Matthew Amado, President and co-founder of LYF.


LYF will focus on producing sublingual nutraceuticals, functional foods, and traditional edibles in their wholly-owned, purpose-built facility in Kelowna, BC, capable of manufacturing over $250,000,000 worth of value-added cannabis products per year once licensed and fully operational.

To fund the final steps of the Company’s strategic plan, LYF is currently looking to raise up to $6,000,000 via a convertible note offering (the “Offering”). Proceeds will be used to order manufacturing and production equipment, business development, hiring of necessary staff, marketing, sales and for general corporate purposes. The Offering will consist of Secured Convertible Debentures, with each note earning 8% interest and exercisable at $0.25 per share for a period of three (3) years. The investment round is open to accredited investors, with a $10,000.00 minimum investment.

The Offering is expected to close on or about December 20, 2019, subject to customary closing conditions and LYF having the right to extend the closing of the Offering at its sole discretion. This announcement is neither an offer to sell nor a solicitation of an offer to buy the convertible notes or the common shares of LYF into which the notes are convertible and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

The convertible notes and any common shares of LYF issuable upon conversion of the notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, or qualified for distribution by prospectus in Canada, and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements, or sold in Canada absent an exemption from the prospectus requirements of Canadian securities laws.

About LYF Food Technologies Inc.

Expertly crafted chocolate, confectionary, raw health foods and baked edibles are what we do best. LYF has over 25 years experience in large-scale food manufacturing for some of the biggest grocery store, health and wellness retailers and pharmacies across Canada, and have combined that expertise with science-led cannabis R&D in infusion technologies, proprietary delivery methods and novel product development.

LYF owns a state-of-the-art 10,500 sqft, purpose built, cannabis specific manufacturing facility with a production capacity of over $250,000,000 of edibles per year in a safe and consistently dosed manner. LYF is well positioned to be a leading manufacturer of white label products turning potential competitors into strategic partners.

For more information please contact:

lyffoods.com // investors@lyffoods.com // 1.833.786.2253

Cautionary Notes

Completion of the Offering is subject to a number of conditions. The Offering cannot close until all required regulatory and corporate approvals are obtained. There can be no assurance that the Offering will be completed as proposed, or at all. Trading in the securities of LYF should be considered highly speculative.

This news release may include forward-looking statements that are subject to inherent risks and uncertainties. All statements within this news release, other than statements of historical fact, are to be considered forward looking. Although LYF believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those described in forward-looking statements. Factors that could cause actual results to differ materially from those described in forward-looking statements include market fluctuations, availability of capital and financing, and general economic, market and business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. LYF does not assume any obligation to update any forward-looking statements except as required under applicable laws.

Source

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 
  • Existing At-The-Market (ATM) program now complete
  • New Preliminary Base Shelf Prospectus Has Been Filed
  • Current Cash Position is Approximately $272 million

NYSE | TSX: ACB

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously filed At-The-Market (“ATM”) program. Because of this, the Company has filed a new preliminary short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada except Quebec and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).

Keep reading... Show less

 Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/66901_b3bb261db486a838_001.jpg

Keep reading... Show less

Inaugural runs of the award-winning and new white-label brands will allow the infused beverage expert to move ahead quickly with commercialization plans

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) (FSE:7BC) (“BevCanna” or the “Company”) is pleased to announce that it has successfully completed the R&D and trial production runs of its exclusively licenced award winning line of Keef Beverages and the white-label beverages the Company is producing for State B Beverages.

Keep reading... Show less

(TheNewswire)

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.

“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.

Keep reading... Show less